CCR4, C-C motif chemokine receptor 4, 1233

N. diseases: 168; N. variants: 1
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE Thus, CCR4 might be a possible therapeutic target for patients with early-stage cancer. 30395826 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE This has culminated in the approval of two glyco-engineered antibodies for cancer therapy: the anti-CCR4 mogamulizumab approved in 2012 and the anti-CD20 obinutuzumab in 2013. 28466278 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 AlteredExpression group BEFREE Mogamulizumab reduces levels of CCR4(+) malignant T cells and also CCR4(+) Tregs in patients with CTCL, which may in turn improve immune profiles.Clin Cancer Res; 21(2); 274-85.©2014 AACR. 25376389 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE This represents the first reported recurrent mutation in a member of the CCR4-NOT complex in cancer. 25544760 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 GeneticVariation group BEFREE These findings implicate somatic gain-of-function CCR4 mutations in the pathogenesis of ATLL and suggest that inhibition of CCR4 signaling might have therapeutic potential in this refractory malignancy. 25488980 2014